Explore Leinco Technologies’ high-quality CD80 antibodies and reagents designed to advance your cancer immunotherapy research. CD80, a highly glycosylated 60 kDa protein within the Ig superfamily, plays a crucial role in immune cell activation during pathogen response and is a vital target in immunotherapy studies.
CD80 works synergistically with CD86 (B7-2) to effectively prime T-cells, initiating the adaptive immune response. Understanding the CD80/CD86 interaction is essential for developing effective cancer treatments. Furthermore, CD80’s interaction with CTLA-4 delivers an inhibitory signal to T-cells, making it a critical checkpoint in immune regulation.
Leinco Technologies provides reliable CD80 antibodies and related products to support research focused on:
- CD80/CTLA-4 pathway inhibition: Investigating novel immune checkpoint inhibitors.
- T-cell activation studies: Analyzing the role of CD80 in anti-tumor immunity.
- Block CD80 in vivo: Use Clone 16-10A1 to Block CD80 in mouse models.
- CD80/CD86 signaling: Exploring the synergistic roles of these co-stimulatory molecules.
- Immunological research: studying the fundamental aspects of immune cell interactions.
Leverage Leinco’s expertise in immunology reagents to accelerate your CD80 research and contribute to advancing cancer immunotherapy. Browse our catalog for high-quality CD80 antibodies.
